Kiniksa Pharmaceuticals International Plc (KNSA) Stock Price, Quote & News

Company Profile

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clin...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 44 78 1431 9100

Website: www.kiniksa.com

Address:

105 Piccadilly, 2nd Floor, London, United Kingdom

BreakoutsHappen Apr. 14 at 10:03 AM

Vix under 19, 50% stocks above ma40. Seems a good day for breakouts. $TIGO $KNSA $ROIV

0 · Reply

jdlman Apr. 11 at 11:47 PM

$KNSA should be a good week

0 · Reply

Night_Owl_Biotech Apr. 3 at 5:36 PM

The attachment notes the 22 commercial-stage bios trading within 10% of their highest closing share price since 12/1/2025 as of 4/2/2026. We count 89 such bios in total in this peer group (25 oncology focused with MCs over $300MM & 64 non-oncology focused with MCs over $800MM). $RPRX $KNSA $AGIO & $TGTX are the non-oncology bios in this peer group all trading at their highest share prices since 12/1/2025. $SNDX closed at its highest closing price in oncology. Thank you Goldman Sachs. SNDX investors may want to look at SNDX trading after Goldman's last upgrade that, our records reflect, was issued on 9/5/25. This is not investment advice.

1 · Reply

Night_Owl_Biotech Apr. 2 at 12:36 AM

Even though $SLNO is up ~20% the last 2 days, SLNO still trades @ meaningfully lower multiples of analyst consensus revenue estimates than peer commercial-stage non-oncology focused bios. The attachment provides the raw data used to calculate these multiples. Note none of the 4 peers generated gross margins over 90% in FY25 where SLNO's gross margins were 99%. Gross margin is not considered when comparing revenue multiples. For perspective, analysts project SLNO to generate more revenues over the next 10 years as $MIRM yet SLNO trades at 1/3 MIRM's market cap. SLNO's cash is roughly 25% of its market cap. This suggests SLNO offers a compelling risk v reward profile if (2 HUGE IFs) analyst consensus revenue estimates are credible AND if Vykat's value proposition merits peer multiples. Again this is in no way to criticize nor bash MIRM, but rather to highlight SLNO. $TARS & $KNSA also trade at lower multiples (even after KNSA's run). $TGTX multiples are after a 20% gains the last 3 weeks

6 · Reply

kiwitc2000 Mar. 31 at 2:51 PM

$KNSA Another bio pick for the short week.

0 · Reply

Night_Owl_Biotech Mar. 21 at 4:53 PM

$SNDX is the best performing comm'l-stage bio stock (in both oncology & non-oncology) as measured by its 3/20/26 close v. its 3.5 month high (since 12/1/25). The attachment lists all 92 commercial-stage oncology (MCs over $300MM) & non-oncology (MCs over $900MM) bio stocks 3/20/26 closing share price v. their 3.5 month high (again since 12/1/25). The table excludes DAWN & DVAX (both recently acquired). The $XBI is more or less unchanged over this time (up 0.5%) Note more than half of SNDX peers are off their recent highs by over 25%. $BCRX comes a close second to SNDX. BCRX's strong share price is likely due to the Betaville Uncooked alert this last week suggesting BCRX is in active M&A negotiations. $KNSA ranks third on the list $OCUL 's share price appears to provide a textbook example of why the odds are shareholder value is maximized via M&A exit in this peer group. As always, do not rely on the attachment. Verify the data points for yourself. This is not investment advice.

3 · Reply

OfficialStocktwitsUser Mar. 10 at 12:59 PM

$KNSA RSI: 54.49, MACD: 0.7641 Vol: 1.39, MA20: 45.45, MA50: 43.42 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

brooklynyycc Mar. 6 at 8:49 PM

$KNSA FMR doubled their holidngs to 1600k last quarter to be 2%, now this quarter they increased to 4800k and became 10% holders

0 · Reply

BillionerOfKing Mar. 3 at 4:07 PM

$KNSA Current Stock Price: $45.59 Contracts to trade: $45.0 KNSA Mar 20 2026 Call Entry: $4.32 Exit: $8.43 ROI: 95% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

sunset_PARK Mar. 2 at 8:52 PM

$CPRX $KNSA $TARS they all moved last 30mins withvolume, similar market cap in bio, any news, any others? Seems not in the same index?

1 · Reply

Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis

Feb 25, 2026, 4:01 PM EST - 6 weeks ago

Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 7:30 AM EST - 7 weeks ago

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

Feb 19, 2026, 4:01 PM EST - 7 weeks ago

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Jan 12, 2026, 7:30 AM EST - 3 months ago

Kiniksa Pharmaceuticals Provides Corporate Update

Jan 7, 2026, 4:01 PM EST - 3 months ago

Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference

Nov 12, 2025, 4:01 PM EST - 5 months ago

Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London

Oct 28, 2025, 7:30 AM EDT - 6 months ago

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

Oct 23, 2025, 4:01 PM EDT - 6 months ago

Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025

Oct 17, 2025, 8:00 AM EDT - 6 months ago

Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis

Aug 28, 2025, 4:01 PM EDT - 8 months ago

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

Jul 29, 2025, 7:30 AM EDT - 9 months ago

Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution

Jul 24, 2025, 4:01 PM EDT - 9 months ago

Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025

Jun 5, 2025, 7:00 AM EDT - 11 months ago

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

Apr 30, 2025, 8:30 AM EDT - 1 year ago

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

Apr 24, 2025, 4:01 PM EDT - 1 year ago

Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

Feb 25, 2025, 7:30 AM EST - 1 year ago

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

Feb 25, 2025, 7:29 AM EST - 1 year ago

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

Feb 20, 2025, 4:01 PM EST - 1 year ago

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Jan 13, 2025, 7:30 AM EST - 1 year ago

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

Jan 6, 2025, 4:01 PM EST - 1 year ago

Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference

Nov 26, 2024, 4:01 PM EST - 1 year ago

Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference

Nov 12, 2024, 4:01 PM EST - 1 year ago

Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference

Oct 29, 2024, 7:30 AM EDT - 1 year ago

Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution

Oct 22, 2024, 4:01 PM EDT - 1 year ago

Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024

Aug 28, 2024, 4:01 PM EDT - 1 year ago

Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference

Jul 23, 2024, 7:30 AM EDT - 1 year ago

Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution

Jul 16, 2024, 4:01 PM EDT - 1 year ago

Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren's Disease

Jun 17, 2024, 8:30 AM EDT - 1 year ago

Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative

Jun 4, 2024, 4:01 PM EDT - 2 years ago

Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 7, 2024, 4:01 PM EDT - 2 years ago

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

Apr 23, 2024, 7:30 AM EDT - 2 years ago

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution

Apr 16, 2024, 4:01 PM EDT - 2 years ago

Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

Apr 2, 2024, 7:30 AM EDT - 2 years ago

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

Feb 28, 2024, 7:30 AM EST - 2 years ago

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution

Feb 21, 2024, 4:01 PM EST - 2 years ago

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

Jan 2, 2024, 4:01 PM EST - 2 years ago

Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference

Oct 31, 2023, 7:30 AM EDT - 2 years ago

Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution

Oct 24, 2023, 4:01 PM EDT - 2 years ago

Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023

Jul 25, 2023, 7:30 AM EDT - 2 years ago

Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution

Jul 17, 2023, 8:00 AM EDT - 2 years ago

Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023

Jun 6, 2023, 4:01 PM EDT - 3 years ago

Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

May 2, 2023, 7:30 AM EDT - 3 years ago

Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution

May 1, 2023, 4:01 PM EDT - 3 years ago

Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023

Feb 28, 2023, 8:00 AM EST - 3 years ago

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution

Feb 27, 2023, 4:01 PM EST - 3 years ago

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on February 28, 2023

Jan 3, 2023, 4:01 PM EST - 3 years ago

Kiniksa Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference

Nov 30, 2022, 4:01 PM EST - 3 years ago

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2022 Biotech SMID Cap Conference

BreakoutsHappen Apr. 14 at 10:03 AM

Vix under 19, 50% stocks above ma40. Seems a good day for breakouts. $TIGO $KNSA $ROIV

0 · Reply

jdlman Apr. 11 at 11:47 PM

$KNSA should be a good week

0 · Reply

Night_Owl_Biotech Apr. 3 at 5:36 PM

1 · Reply

Night_Owl_Biotech Apr. 2 at 12:36 AM

6 · Reply

kiwitc2000 Mar. 31 at 2:51 PM

$KNSA Another bio pick for the short week.

0 · Reply

Night_Owl_Biotech Mar. 21 at 4:53 PM

3 · Reply

OfficialStocktwitsUser Mar. 10 at 12:59 PM

0 · Reply

brooklynyycc Mar. 6 at 8:49 PM

$KNSA FMR doubled their holidngs to 1600k last quarter to be 2%, now this quarter they increased to 4800k and became 10% holders

0 · Reply

BillionerOfKing Mar. 3 at 4:07 PM

0 · Reply

sunset_PARK Mar. 2 at 8:52 PM

$CPRX $KNSA $TARS they all moved last 30mins withvolume, similar market cap in bio, any news, any others? Seems not in the same index?

1 · Reply

erevnon Feb. 25 at 2:16 PM

Wedbush maintains Kiniksa Pharmaceuticals $KNSA at Outperform and raises the price target from $50 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

StocktwitsEarnings Feb. 24 at 12:43 PM

$KNSA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.19 up 258.33% YoY • Reported revenue of $202.13M up 64.95% YoY • Kiniksa expects 2026 ARCALYST net product revenue to be between $900M and $920M. Kiniksa also anticipates its current operating plan will remain cash flow positive on an annual basis.

0 · Reply

Quantumup Feb. 19 at 7:28 PM

Canaccord Genuity🏁 $KNSA Buy-$62 $REGN $NVS $CRDL Here's what Canaccord said in its initiation report: Kiniksa is a commercial-stage biotech company with a strong focus on developing treatments for recurrent pericarditis (RP), as well as additional inflammatory cardiovascular diseases. The company's approved product, Arcalyst (rilonacept) is the first and currently only FDA-approved therapy for RP treatment. RP is a challenging heart disease characterized by relapses of inflammation in the pericardium, a thin tissue sac surrounding the heart. The disease is often associated with sharp chest pain. Once a patient has a first recurrence, the risk of further recurrence is high and can be ~50% among those without proper medical attention. In the U.S., RP impacts over 40,000 people. According to Future Market Insights, the pericarditis treatment market was estimated to be valued at $4.1B in 2025 and is projected to reach $6.8B by 2035.

0 · Reply

stockpicker63 Feb. 19 at 4:41 PM

1. Kiniksa Pharmaceuticals (KNSA) $KNSA is currently in a very strong bullish phase, driven by both technical breakouts and fundamental growth. Trend: The stock recently reached a new All-Time High (ATH) around $45.70. The medium-term trend (Rising Trend Channel) indicates continued optimism among investors. Moving Averages: All major averages (SMA 20, 50, and 200) are signaling “Buy.” The price is trading well above these lines, indicating strong momentum. RSI (14): Currently around 60–65. This is elevated but not yet in the “overbought” zone (>70), suggesting there is still room for further upside before reaching saturation. Spport & Resistance: Resistance: Psychological level at $50.00 Support: First major support is around $41.12 (the price level following the brief dip in January) SST-AI-Score: 9/10 Ensemble Score: Very High Signal: Strong Buy Earnings Date: February 24, 2026 Strategic Note: Tuesday’s earnings release. Expected earnings growth (EPS) is an impressive +341% year-over-year.

0 · Reply

OfficialStocktwitsUser Feb. 18 at 5:47 PM

$KNSA RSI: 63.19, MACD: 0.9077 Vol: 1.12, MA20: 43.95, MA50: 42.40 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Night_Owl_Biotech Feb. 18 at 3:10 AM

Commercial-stage bios trading near 4.5 highs since 10/1/2025. All 5 below trading at 4.5 month highs $GERN has been trading between $1.25 & $1.45 since April 2025, and after JPM. If anyone is aware why GERN is running please share. $TWST is way up consistently since 2/2/26 after big guidance for FY2026. $PGEN Consensus for Papzimeos as new first-line SOC for Papillomatosis per 1/20/26 PR $INVA There is no PR nor SEC filing since 12/25 outside of Nuzolvence approval $KNSA $900MM in FY26 product revenue guidance from $677 in FY25 (approval in 3/2021). Still trading at 4.0X FY2026 For entertainment purposes only.

1 · Reply

PumpProtector Feb. 4 at 9:21 AM

$KNSA biotech, pipeline catalysts key

1 · Reply

mmtiddy Jan. 28 at 8:05 PM

$CRDL Dude you really want me to go over this, I can submit an entire thesis on this company, their backstory, why they were created, the amount of times they diluted, the amount of institutions that exited, the marketing budget spent on this stock, their drug comparison to $KNSA, And call a spade a spade, this isnt a life changing drug, its an addition to a treatment, and they fked everyone over trying to position themselves more than they arent, especially those republicans

1 · Reply

OfficialStocktwitsUser Jan. 15 at 12:12 PM

$KNSA RSI: 37.70, MACD: -0.2051 Vol: 1.17, MA20: 41.68, MA50: 41.13 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Happy_Feet19 Jan. 13 at 10:53 PM

$KNSA Why is this stock price going down? The just released their revenue forecast of almost $1 Billion in 2026. Insane growth. Why are people selling? Analyst are at $55. (which on the low side).

1 · Reply

TradeThePool Jan. 13 at 7:14 AM

$KNSA Kiniksa Pharmaceuticals: The "Earn" Story Begins 🚀 This isn't a cash-burn bio play anymore. Q3 Net Income = $18.4M. Revenue +61% YoY to $180.9M. The Bull Case: 1. Monopoly: ARCALYST dominates pericarditis. 2. Growth: Only 15% market penetration so far. 3. Pipeline: Monthly injection (KPL-387) coming to lock in patients. Analysts say $54. We are at $42. Gap needs to close. 📈 #biotech #earnings #breakout #long

0 · Reply

NotGamblingIfWinning Jan. 12 at 3:08 AM

$KNSA what is reasonable sell price for this stock over next 5-10 years?

0 · Reply

Market Cap	3.60B
Revenue (ttm)	677.56M
Net Income (ttm)	59.01M
EPS (ttm)	N/A
PE Ratio	63.96
Forward PE	39.88
Profit Margin	8.71%
Debt to Equity Ratio	0.00

Volume	350,900
Avg Vol	610,774
Day's Range	N/A - N/A
Shares Out	76.54M
Stochastic %K	52%
Beta	0.06
Analysts	Strong Sell
Price Target	$57.38